U.S. Glp-1 Receptor Agonist Market Size & Outlook, 2026-2033
Global Market
Related Markets
U.S. glp-1 receptor agonist market highlights
- The U.S. glp-1 receptor agonist market generated a revenue of USD 47,983.1 million in 2025 and is expected to reach USD 130,602.1 million by 2033.
- The U.S. market is expected to grow at a CAGR of 12% from 2026 to 2033.
- In terms of segment, semaglutide (ozempic, wegovy, rybelsus) was the largest revenue generating product in 2025.
- Semaglutide (Ozempic, Wegovy, Rybelsus) is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2025 | USD 47,983.1 million |
| Market revenue in 2033 | USD 130,602.1 million |
| Growth rate | 12% (CAGR from 2026 to 2033) |
| Largest segment | Semaglutide (ozempic, wegovy, rybelsus) |
| Fastest growing segment | Semaglutide (Ozempic, Wegovy, Rybelsus) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound), Dulaglutide (Trulicity), Liraglutide (Victoza, Saxenda), Others (Byetta, Bydureon, SOLIQUA) |
| Key market players worldwide | Eli Lilly and Co, Sanofi SA, Novo Nordisk A/S ADR, AstraZeneca PLC |
Other key industry trends
- In terms of revenue, U.S. accounted for 72.3% of the global glp-1 receptor agonist market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 1,204.0 million by 2033.
The U.S. accounted for a significant revenue share of the GLP-1 receptor agonist market in 2023. The market growth is driven by the rising prevalence of type 2 diabetes, which affects over 30 million people, and an increasing focus on obesity management, with more than 40% of U.S. adults classified as obese.
This high prevalence of target diseases is anticipated to drive the demand for GLP-1 agonist drugs, further driving the market. Furthermore, supportive government initiatives and rising investment in R&D are other factors propelling the U.S.
GLP-1 receptor agonist market. Moreover, pharmaceutical companies are actively focusing on the development of GLP-1 receptor agonists in response to the blockbuster success of Novo Nordisk’s Wegovy and Ozempic, as well as Eli Lilly’s Zepbound and Mounjaro.
No credit card required*
Publish Date: Dec 23, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Glenmark Pharmaceuticals | View profile | 10001+ | Andheri, Maharashtra, India, Asia | www.glenmarkpharma.com |
U.S. GLP-1 Receptor Agonist Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to GLP-1 Receptor Agonist Market Outlook will help companies and investors design strategic landscapes.
Semaglutide (Ozempic, Wegovy, Rybelsus) was the largest segment with a revenue share of 59.94% in 2025.
Horizon Databook has segmented the U.S. glp-1 receptor agonist market based on semaglutide (ozempic, wegovy, rybelsus), tirzepatide (mounjaro, zepbound), dulaglutide (trulicity), liraglutide (victoza, saxenda), others (byetta, bydureon, soliqua) covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. accounted for a significant revenue share of the GLP-1 receptor agonist market in 2023. The market growth is driven by the rising prevalence of type 2 diabetes, which affects over 30 million people, and an increasing focus on obesity management, with more than 40% of U.S. adults classified as obese.
This high prevalence of target diseases is anticipated to drive the demand for GLP-1 agonist drugs, further driving the market. Furthermore, supportive government initiatives and rising investment in R&D are other factors propelling the U.S.
GLP-1 receptor agonist market. Moreover, pharmaceutical companies are actively focusing on the development of GLP-1 receptor agonists in response to the blockbuster success of Novo Nordisk’s Wegovy and Ozempic, as well as Eli Lilly’s Zepbound and Mounjaro.
- U.S. Glp-1 Receptor Agonist Market Product Outlook (Revenue, USD Million , 2021-2033)
- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Tirzepatide (Mounjaro, Zepbound)
- Dulaglutide (Trulicity)
- Liraglutide (Victoza, Saxenda)
- Others (Byetta, Bydureon, SOLIQUA)
- U.S. Glp-1 Receptor Agonist Market Application Outlook (Revenue, USD Million , 2021-2033)
- Type 2 Diabetes Mellitus
- Obesity / Chronic Weight Management
- Cardiovascular Risk
- U.S. Glp-1 Receptor Agonist Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Injectable / Parenteral
- Oral
- U.S. Glp-1 Receptor Agonist Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to GLP-1 Receptor Agonist Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of GLP-1 Receptor Agonist Market Outlook databook
- Our clientele includes a mix of GLP-1 Receptor Agonist Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. GLP-1 Receptor Agonist Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. GLP-1 Receptor Agonist Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Glp-1 Receptor Agonist Market, 2021-2033 (US$M)
U.S. glp-1 receptor agonist market statistics, by product, 2021-2033 (US$M)
